Sex: M
Vaccine: COVID19
Symptoms: Haemorrhage, Skin papilloma, Vaccination site rash, Vaccination site swelling, Vaccination site vesicles
Clinical narrative: Red dot at the injection site; She describes the area as bright red bulbous blood blister wart type area; it grew to large size as bold as blood vessel; She describes the area as bright red bulbous blood blister wart type area; The area was nicked and began to bleed; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the parent.  A 12 year-old male patient received bnt162b2 (BNT162B2), administration date 26Jan2022 (Batch/Lot number: unknown) at the age of 12  as dose number unknown (booster), single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: Covid-19 vaccine (Dose number: Unknown, Manufacturer: Unknown), for Covid-19 immunization.  The following information was reported: HAEMORRHAGE (medically significant) with onset 2022, outcome "unknown", described as "The area was nicked and began to bleed"; VACCINATION SITE RASH (non-serious) with onset Jan2022, outcome "recovered" (2022), described as "Red dot at the injection site"; VACCINATION SITE VESICLES (non-serious), SKIN PAPILLOMA (non-serious) all with onset 2022, outcome "unknown" and all described as "She describes the area as bright red bulbous blood blister wart type area"; VACCINATION SITE SWELLING (non-serious) with onset 2022, outcome "unknown", described as "it grew to large size as bold as blood vessel". The events "the area was nicked and began to bleed", "red dot at the injection site", "she describes the area as bright red bulbous blood blister wart type area", "it grew to large size as bold as blood vessel" and "she describes the area as bright red bulbous blood blister wart type area" were evaluated at the physician office visit and emergency room visit. Therapeutic measures were not taken as a result of haemorrhage, vaccination site rash, vaccination site vesicles, vaccination site swelling, skin papilloma.  Clinical information: Patient who was seeking information on a adverse reaction her 12-year-old son experienced with the Pfizer Covid 19 vaccine booster dose.The mother and son both received the booster dose injection on 26Jan2022. The mother only experienced a red dot at injection site that eventually went away. Her son she states had a red dot at the injection site that was only a small red dot for 5 weeks after injection. She states that at week 5.5 or 6 the dot grew seemingly overnight. She describes the area as bright red bulbous blood blister wart type area. She states that it didn't hurt but grew. The area was nicked and began to bleed. She reports that it bled for over 2 hour straight. He was taken to the ER and has also seen his pediatrician twice since then for this issue. The pediatrician does not know what the area is. She states that everyone at the doctors over was concerned with the area and stated that they had never seen something like this. Patient had not taken any prior vaccination within 4 weeks. The patient had not taken any medication for treatment.  The lot number for bnt162b2 was not provided and will be requested during follow up.